Demonstrating Purpose, Creating Value


Annual Reporting in 2017/18: 

The impact of changes to the UK Corporate Governance Code are already being seen in businesses’ annual reporting. In their yearly review, EY pulls out highlights and provides an ‘acid test’ to apply to your narrative report.

Review highlights include:

- 41 percent of companies clearly link their purpose to their strategy

- 65 percent of companies describe the methods used to engage with stakeholders such as customers, suppliers, communities and governments

- 74 percent of companies have a standalone section on corporate responsibility / sustainability rather than using a more integrated approach

- 15 percent of reports provide detail on the impact of initiatives taken to improve diversity

Share this with your Community





Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Jane Pateman, NED at Knights plc: What Changes from CPO to NED?

Moving from CPO to NED means shifting from execution to influence, challenge and oversight. In this episode, Bridgette Hall, Senior Editor at Criticaleye, speaks with Jane Pateman, NED at Knights plc and Critical...


Christina Chan, CFO, Asia Pacific at Marriott International on Leading as a Regional CFO

Christina Chan, CFO, Asia Pacific excluding China for Marriott International spoke to us about her career journey, leading as a regional CFO and finance as a driver for growth. Discussion points include: ...


Burger King UK CFO Tim Doubleday on What Makes a Great Private Equity CFO

Tim Doubleday, Group CFO at Burger King UK, joins Jacob Ambrose Willson, Senior Editor at Criticaleye, to discuss what it takes to succeed as a CFO in a private equity-backed business. Tim shares his perspective ...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 241




London Stock Exchange Group Hitachi Solutions Stream NATS Global Payments Drax Group plc AlixPartners Rolls-Royce Legal & General E.ON UK British Land Mayborn Group Lightsource bp LACE Partners GlaxoSmithKline plc NatWest Group